Physician profile
Mark Corbett
NPI 1528064508
$137,884.75
in general payments reported to CMS, 2019-2025
35 companies · $109 in 2025
The $109 reported for 2025 was less than what a typical Allergy & Immunology provider received nationally (typical 2025 total: $1,138).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $70K · 2020: $20K · 2021: $23K · 2022: $8,156 · 2023: $17K · 2025: $109.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $12K · Food and Beverage: $2,818 · Honoraria: $1,563 · Consulting Fee: $970.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $11,510.39 |
| Food and Beverage | $2,818.08 |
| Honoraria | $1,563.00 |
| Consulting Fee | $970.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Regeneron Healthcare Solutions, INC. | $49,444.13 | 2019-2023 | Dupixent |
| Optinose US, INC. | $19,594.25 | 2019-2022 | |
| Takeda Pharmaceuticals U.S.A., INC. | $12,569.14 | 2020-2023 | Takhzyro, Cuvitru |
| Genzyme Corporation | $10,841.87 | 2019-2025 | |
| Astrazeneca Pharmaceuticals LP | $9,851.50 | 2019-2023 | Fasenra, Breztri, Tezspire |
| Biocryst Pharmaceuticals, INC. | $8,805.87 | 2019-2022 | |
| Covis Pharma Gmbh | $5,600.91 | 2019-2022 | |
| Pharming Healthcare, INC. | $4,134.14 | 2019-2023 | Ruconest |
| Alk-Abello, INC | $4,078.15 | 2019-2023 | Odactra, Ragwitek, Grastek |
| Pfizer INC. | $2,692.56 | 2020-2023 | |
| Abbvie INC. | $2,660.42 | 2022 | |
| Csl Behring | $2,465.59 | 2019-2023 | Haegarda, Hizentra |
| Blueprint Medicines Corporation | $1,706.16 | 2022-2023 | |
| Glaxosmithkline, LLC. | $647.17 | 2019-2023 | Nucala |
| Biocryst US Sales Co., LLC | $500.29 | 2021-2023 | Orladeyo |
Show all 35 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Sanofi-Aventis U.S. LLC | $345.08 | 2019-2021 | |
| Teva Pharmaceuticals USA, INC. | $329.21 | 2019-2022 | |
| Kaleo, INC. | $319.78 | 2019-2023 | Auvi-Q |
| Genentech, INC. | $303.93 | 2022 | |
| Amgen INC. | $246.50 | 2020-2023 | Tezspire |
| Novartis Pharmaceuticals Corporation | $163.14 | 2019-2022 | |
| Genentech USA, INC. | $104.65 | 2019-2023 | Xolair |
| Boehringer Ingelheim Pharmaceuticals, INC. | $89.08 | 2020-2022 | |
| Merz North America, INC. | $78.37 | 2019 | |
| Grifols USA, LLC | $56.61 | 2021-2023 | Prolastin-C Liquid, Xembify |
| Adma Biomanufacturing LLC | $54.85 | 2021-2022 | |
| Aimmune Therapeutics, INC. | $42.80 | 2021 | |
| Leo Pharma INC. | $33.69 | 2022-2023 | Adbry |
| Merck Sharp & Dohme LLC | $24.98 | 2023 | |
| Incyte Corporation | $22.92 | 2022 | |
| Octapharma USA, INC. | $18.41 | 2023 | Panzyga |
| Circassia INC. | $17.76 | 2019 | |
| Shire North American Group INC | $15.83 | 2019 | |
| Hikma Pharmaceuticals USA | $13.66 | 2023 | Ryaltris |
| Cumberland Pharmaceuticals, INC. | $11.35 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Mark Corbett listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.